International study supports dupilumab for treatment of moderate-to-severe asthma in children
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11. The findings of the international multicenter Liberty Asthma VOYAGE trial, reported Dec. 9 in the New England Journal of Medicine, supported approval of dupilumab for the treatment of moderate-to-severe asthma in this age group by the Food and Drug Administration in October. "This is a really important advance for children with moderate-to-severe asthma and their families," said Leonard Bacharier, MD, an asthma specialist at Monroe Carell Jr. Children's Hospital at Vanderbilt and the international lead investigator for the trial. "As asthma gets increasingly severe, the burden becomes substantial, impacting the…